Progenra, Inc. ("Progenra") announced today that it has entered into a research collaboration with Ono Pharmaceutical Co., Ltd ("Ono"). Under the agreement, Progenra will collaborate with Ono to conduct assay development and high throughput screening by using Progenra's proprietary technology on multiple targets in the ubiquitin pathway. Terms of the agreement were not disclosed.
“We are pleased that Progenra's unique UbiPro™ Drug Discovery Platform is gaining traction outside the US and that a major pharmaceutical company such as Ono has agreed to collaborate with Progenra on the ubiquitin and ubiquitin-like protein pathways”
"We are pleased that Progenra's unique UbiPro™ Drug Discovery Platform is gaining traction outside the US and that a major pharmaceutical company such as Ono has agreed to collaborate with Progenra on the ubiquitin and ubiquitin-like protein pathways," said Tauseef Butt, President and CEO of Progenra. "Given Progenra's accumulated knowledge and know-how in this space and Ono's proven drug discovery record, we are confident of success."
Decades of research push cytomegalovirus vaccine closer to reality